Temperature-sensitive pharmaceuticals—biologics, insulin, vaccines, and certain oral formulations—represent a growing share of pharmaceutical revenue and carry disproportionate risk when the cold chain is compromised. Product degradation, patient safety events, and regulatory penalties are all possible consequences of a single temperature excursion.

At the outset of this project, the client had a fragmented cold chain: some regional distributors owned walk-in cold rooms that were not qualified or monitored to GSP standards, temperature excursions were discovered retrospectively through customer complaints, and documentation was largely manual and inconsistent.

Our engagement began with a detailed supply chain mapping exercise that traced every temperature-sensitive SKU from the manufacturing facility through to the end customer—covering 11 product categories, 3 shipping lanes (air, rail, road), and 40+ distribution partners. For each node, we assessed infrastructure, documentation, and personnel competency.

Based on the mapping, we designed a hub-and-spoke architecture with five regional distribution centres in Jaipur (hub), Delhi, Mumbai, Hyderabad, and Kolkata. Each hub was equipped with validated cold rooms (2°C–8°C) and ambient-controlled areas (15°C–25°C) with automated BMS monitoring. Twenty-eight spoke locations—one per key district cluster—were equipped with validated cool boxes and IoT loggers.

The IoT temperature monitoring system used GPRS-enabled data loggers with 15-minute recording intervals, automatic SMS and app alerts on excursion, and a cloud dashboard with shipment-level audit trails accessible by the quality team in real time. All loggers were calibrated to NABL-accredited standards and recalibrated every six months.

SOP development covered the full operational lifecycle: ordering, receiving, put-away, pick-pack, dispatch, in-transit monitoring, excursion investigation, and product rejection or quarantine. Each SOP was reviewed against Schedule M and GSP guidelines, and incorporated deviation management with escalation matrices.

The outcome was a network that reduced temperature excursion incidents from 11% to 1.2% within six months of full deployment—a reduction that translated directly to improved product quality, reduced wastage, and a significantly cleaner regulatory record.